Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, has completed construction of the early phase clinical cGMP manufacturing facility as a part of its overall master plan for a 75,000 sq ft lentiviral and retroviral process development and cGMP vector production facility in Indianapolis, Indiana.   Genezen also announced the next phase of its expansion to support increased lentiviral and re...